Phathom Pharmaceuticals, Inc.

PHATNASDAQHealthcareBiotechnology

$6.92- (-)1Y −42.13%

As of Oct 16, 2026 close

Market cap: $628.10M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $6.52$18.31
Volume (live): -
Avg. volume (3M): 1.37M

Phathom Pharmaceuticals, Inc. (PHAT) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Phathom Pharmaceuticals, Inc. stock.

Analyst Consensus Rating

Investment consensus from 8 professional research analysts

Consensus Rating

Buy

Based on 8 unique analysts

Medium Confidence∞:1 Buy/Sell

Average Price Target

$19.29

+178.76% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest PHAT Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Sep 21, 2026	Matthew Caufield	HC Wainwright	Maintains	Buy	$26.00
Sep 9, 2026	Daniel Clark	Leerink Partners	Initiates	Hold	$10.00
Aug 17, 2026	Jenna Davidner	Barclays	Maintains	Buy	$14.00
Jul 31, 2026	Chase Knickerbocker	Craig-Hallum	Reiterates	Buy	$22.00 → $20.00 −2.00 (−9.1%)
Jul 31, 2026	Yatin Suneja	Guggenheim	Maintains	Buy	$25.00 → $22.00 −3.00 (−12.0%)
Jul 31, 2026	Martin Auster	Raymond James	Maintains	Buy	$21.00
Jul 30, 2026	Joseph Stringer	Needham	Maintains	Buy	$28.00 → $22.00 −6.00 (−21.4%)
Jul 30, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Hold	-

Matthew Caufield

HC Wainwright

BuyMaintains

$26.00

Sep 21

Daniel Clark

Leerink Partners

HoldInitiates

$10.00

Sep 9

Jenna Davidner

Barclays

BuyMaintains

$14.00

Aug 17

Chase Knickerbocker

Craig-Hallum

BuyReiterates

$22.00 → $20.00

Jul 31

Yatin Suneja

Guggenheim

BuyMaintains

$25.00 → $22.00

Jul 31

Martin Auster

Raymond James

BuyMaintains

$21.00

Jul 31

Joseph Stringer

Needham

BuyMaintains

$28.00 → $22.00

Jul 30

Zacks Equity Research

HoldInitiates Coverage

Jul 30

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Sep 21, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for PHAT?

The analyst consensus rating for PHAT is Buy, based on the latest ratings from 8 analysts over the last 90 days.

What is the average price target for PHAT?

The average 12-month price target for PHAT is $19.29, representing an upside of 178.8% from the Oct 16, 2026 close of $6.92.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.